We are live on ! Find out more
XDNA

Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA

Delisted

XDNA was delisted on the 30th of November, 2023.

Back to rankings

3 hedge funds and large institutions have $1.54M invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

448% more capital invested

Capital invested by funds: $281K → $1.54M (+$1.26M)

50% more funds holding

Funds holding: 2 → 3 (+1)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$939K
2
Citadel Advisors
Citadel Advisors
Florida
+$306K
3
UBS Group
UBS Group
Switzerland
+$67.9K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$1.19M +$939K +74,210 +271%
Citadel Advisors
2
Citadel Advisors
Florida
$284K +$306K +24,211 New
UBS Group
3
UBS Group
Switzerland
$65K +$67.9K +5,367 +3,554%

XDNA Hedge Fund Activity: Q3 2022 in Review

3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q3 2022, worth a combined $1.54M — up 448% from $281K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XDNA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, adding an estimated $939K.

  • 3 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q3 2022, up from 2 in Q2 2022.
  • Funds reported $1.54M of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q3 2022, up 448% quarter-over-quarter.
  • 1 fund opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q3 2022 and 0 closed out, a net change of +1 holder.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF buyer in Q3 2022 was Jane Street, an estimated $939K added.

Based on aggregated 13F filings for Q3 2022.